“ I provide strategic advice to help clients achieve their business objectives in major corporate transactions.
Jim has extensive experience representing private and public companies and investors in significant business transactions from formation through liquidity. His practice focuses on mergers and acquisitions, venture capital financings, and emerging company counseling. His clients span a broad range of industries, including biopharmaceutical, artificial intelligence, medical device, e-commerce, cybersecurity, software, Internet, social media, semiconductor, unmanned vehicles, AgTech, consumer products, finance, Cleantech, and energy.
Jim advises clients on private and public acquisitions on both the buy-side and sell-side across numerous transaction structures, including equity purchases, asset purchases, mergers, acquisitions and divestitures of divisions and subsidiaries, cross-border transactions, and auctions. He has represented buyers and sellers in acquisitions and divestitures ranging from $1 million to more than $1 billion.
Jim counsels emerging and established life sciences and technology companies in equity financings and general corporate matters, and angel, corporate, and venture capital investors in investments in such companies. He has represented clients in over $2 billion in equity and debt financings ranging from seed rounds to $100 million-plus later-stage rounds.
In addition, Jim represents public companies in public offerings, other capital markets transactions, and SEC reporting and compliance matters, and advises boards of directors on corporate governance issues.
Jim Krenn serves on the Board of Directors of the San Diego Entrepreneurs Exchange.
- California: Recognized as Best of the Bar – San Diego Business Journal 2015
Mergers + Acquisitions
- ACEA Biosciences
Represented this medical instruments company in its sale to Agilent Technologies (NYSE: A) for $250 million.
- Alaska Energy & Resources Company
Represented this parent company of a regulated electric utility in Alaska in its $170 million sale to Avista (NYSE: AVA).
- Astute Medical
Represented this medical diagnostic company focused on high-risk medical conditions and diseases in its $90 million sale to bioMérieux (EPA: BIM).
- B. Riley Financial (NASDAQ: RILY)
Represented this diversified financial services company in its $53 million private placement and merger with investment banking firm B. Riley & Co.
Represented this private equity-backed developer and manufacturer of laboratory consumables and liquid handling solutions in its sale to Mettler-Toledo (NYSE: MTD) for an undisclosed sum.
- California Cryobank
Represented this private equity-backed leader in reproductive tissue donor services and stem cell banking in multiple acquisitions.
- Clean Energy Fuels (NASDAQ: CLNE)
Represented this provider of natural gas as an alternative fuel for vehicle fleets in its sale for up to $180 million of components of its renewable natural gas business to BP (NYSE: BP).
- Cogent (NASDAQ: COGT)
Represented this biometric identification solutions provider in its $943 million sale to 3M (NYSE: MMM).
- Deere & Company (NYSE: DE)
Represented this agricultural, construction, and forestry machinery corporation in its announced acquisition of the precision planning unit of Monsanto (NYSE: MON) for an undisclosed sum.
- Mentor (NYSE: MNT)
Represented this leading supplier of medical products for the global aesthetic market in its $1.12 billion sale to Johnson & Johnson (NYSE: JNJ).
- Mitchell International
Represented this developer of smart technology solutions that simplify and accelerate claims handling, repair processes, and pharmacy transactions in its acquisition of Cogent Works for an undisclosed sum.
- Safebuilt Insurance Services
Represented this managing general agent that utilizes a proprietary, intelligent distribution channel to provide the full continuum of insurance products in its sale to Integrated Specialty Coverages for an undisclosed sum.
Represented this provider of high-power solid-state amplifiers in its $137 million sale to Spacenet, a subsidiary of Gilat Satellite Networks (NASDAQ: GILT).
- ACEA Biosciences
Represented this developer of cell analysis instrumentation technologies in its $30 million Series E Preferred Stock financing.
- Adicet Bio
Represented this biopharmaceutical company focused on the development of cutting-edge allogeneic immunotherapies for cancer and other diseases in its Series A financing of up to $51 million, and $80 million Series B financing.
- Astute Medical
Represented this medical diagnostic company focused on high-risk medical conditions and diseases in over $200 million of equity and debt financings.
- California Cryobank
Represented this private equity-backed leader in reproductive tissue donor services and stem cell banking in multiple equity and debt financings.
- Forward Ventures
Represented this entity as an investor in multiple equity financings, convertible debt financings, and M&A transactions, including transactions involving HemaQuest Pharmaceuticals, LigoCyte Pharmaceuticals, Ambit Biosciences, and Syndax Pharmaceuticals.
- Greenoaks Capital Partners
Represented this entity and its affiliates as investors in over $100 million in equity financings, debt financings, and secondary transactions, including Coupang and several other prominent e-commerce companies.
- Oak Investment Partners
Represented this entity as an investor in multiple equity financings, including MobiTV and Brit Media.
Represented this artificial intelligence and machine learning software infrastructure provider in its $93 million Series B financing.
- Rakuten Medical
Represented this biotechnology company developing a new class of precision targeted oncologic drugs in over $470 million of equity financings.
- Solarflare Communications
Represented this provider of application-intelligent networking I/O software and hardware platforms in over $200 million of equity and debt financings.
Represented this agriculture technology company focused on seed genetics in over $150 million of equity financings.
- Western Digital Capital
Represented this entity as an investor in multiple equity financings, including investments in Hightail and Upthere.